Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumours

被引：0
|
作者：
Patterson, D. M.
Ross, P.
Koetz, B.
Saleem, A.
Stratford, M.
Stirling, J.
Padhani, A.
Asselin, M.
Price, P.
Rustin, G. J.
机构：
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Canc Res UK, London, England
[3] Wolfson Mol Imaging Ctr, Manchester, Lancs, England
[4] Gray Canc Inst, Northwood, Middx, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14146
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis
    Linh Nguyen
    Theodora Fifis
    Christopher Christophi
    [J]. BMC Cancer, 16
  • [32] Phase I study of CYT997, a novel cytotoxic and vascular disrupting agent, given as a 24-hour intravenous infusion to patients with advanced solid tumours
    Lickliter, J.
    Smith, G.
    Burge, M.
    Coulthard, A.
    Wyld, D.
    Wilks, A.
    Vasey, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancer
    Lickliter, J.
    Francesconi, A.
    Smith, G.
    Burge, M.
    Coulthard, A.
    Rose, S.
    Griffin, M.
    Wilks, A.
    Wyld, D.
    Vasey, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors
    Ricart, Alejandro D.
    Ashton, Edward A.
    Cooney, Matthew M.
    Sarantopoulos, John
    Brell, Joanna M.
    Feldman, Maria A.
    Ruby, Kale E.
    Matsuda, Kazuko
    Munsey, Mark S.
    Medina, Gerardo
    Zambito, Angela
    Tolcher, Anthony W.
    Remick, Scot C.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (04) : 959 - 970
  • [35] A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors
    Alejandro D. Ricart
    Edward A. Ashton
    Matthew M. Cooney
    John Sarantopoulos
    Joanna M. Brell
    Maria A. Feldman
    Kale E. Ruby
    Kazuko Matsuda
    Mark S. Munsey
    Gerardo Medina
    Angela Zambito
    Anthony W. Tolcher
    Scot C. Remick
    [J]. Cancer Chemotherapy and Pharmacology, 2011, 68 : 959 - 970
  • [36] PHASE I STUDY OF OMBRABULIN, A VASCULAR DISRUPTING AGENT (VDA), ADMINISTERED EVERY 3 WEEKS TO JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Kurata, T.
    Murakami, H.
    Fujisaka, Y.
    Kiyota, H.
    Hayashi, H.
    Tanaka, K.
    Nakagawa, K.
    Onozawa, Y.
    Watanabe, J.
    Yamamoto, N.
    Aoyama, T.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 110 - 110
  • [37] Phase I trial of OXi4503: positron emission tomography (PET) analysis shows early effects on tumour perfusion that predict metabolic response
    Price, P.
    Asselin, M. C.
    Kotz, B.
    Charnley, N.
    Watkins, G.
    Rustin, G. J. S.
    Balkissoon, J.
    Goldberg, Z.
    Saleem, A.
    [J]. EJC SUPPLEMENTS, 2010, 8 (07): : 120 - 121
  • [38] Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.
    Tresca, P.
    Tosi, D.
    van Doorn, L.
    Fontaine, H.
    Gaast, A. V.
    Veyrat-Follet, C.
    Oprea, C.
    Dieras, V.
    Eskens, F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique
    Salmon, Howard W.
    Mladinich, Christopher
    Siemann, Dietmar W.
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (17) : 3073 - 3078
  • [40] Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas
    Mita, A. C.
    Yee, L. K.
    Papadopoulos, K. P.
    Heath, E. I.
    Romero, O.
    Lloyd, G. K.
    Cropp, G.
    Spear, M. A.
    Mita, M. M.
    LoRusso, P. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345